Literature DB >> 23114642

The emerging anti-proliferative role of Nutlin-3 in the pathogenesis of systemic malignancies.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23114642      PMCID： PMC3566052          DOI： 10.4161/cbt.22629

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  10 in total

1.  Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer.

Authors:  Mirela Nadler-Milbauer; Lior Apter; Ygal Haupt; Sue Haupt; Yechezkel Barenholz; Tamara Minko; Abraham Rubinstein
Journal:  J Drug Target       Date:  2011-12       Impact factor: 5.121

2.  Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation.

Authors:  Palanisamy Marimuthu; Kamal Kaur; Umadevi Kandalam; Vandana Jasani; Nidha Bukhari; Michelle Nguyen; Alleesa Abdul; Farheen F Pervez; Appu Rathinavelu
Journal:  J Med Food       Date:  2010-12-27       Impact factor: 2.786

3.  Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Authors:  Tongsen Zheng; Jiabei Wang; Xuan Song; Xianzhi Meng; Shangha Pan; Hongchi Jiang; Lianxin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-20       Impact factor: 4.553

4.  Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.

Authors:  Fengchun Ye; Ali Abdul Lattif; Jianping Xie; Aaron Weinberg; Shoujiang Gao
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

5.  Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.

Authors:  Shinji Endo; Kenji Yamato; Sachiko Hirai; Toshikazu Moriwaki; Kuniaki Fukuda; Hideo Suzuki; Masato Abei; Ichiro Nakagawa; Ichinosuke Hyodo
Journal:  Cancer Sci       Date:  2011-01-12       Impact factor: 6.716

6.  Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.

Authors:  Yiwei Zhang; Qi Zhang; Shelya X Zeng; Yu Zhang; Lindsey D Mayo; Hua Lu
Journal:  Cancer Biol Ther       Date:  2012-08-01       Impact factor: 4.742

7.  Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

Authors:  Stéphane Supiot; Richard P Hill; Robert G Bristow
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

8.  Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.

Authors:  Anwesha Dey; E T Wong; P Bist; V Tergaonkar; David P Lane
Journal:  Cell Cycle       Date:  2007-06-27       Impact factor: 4.534

9.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Authors:  M Michaelis; F Rothweiler; S Barth; J Cinatl; M van Rikxoort; N Löschmann; Y Voges; R Breitling; A von Deimling; F Rödel; K Weber; B Fehse; E Mack; T Stiewe; H W Doerr; D Speidel; J Cinatl
Journal:  Cell Death Dis       Date:  2011-12-15       Impact factor: 8.469

10.  Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.

Authors:  Ian R Logan; Hesta V McNeill; Susan Cook; Xiaohong Lu; John Lunec; Craig N Robson
Journal:  Prostate       Date:  2007-06-01       Impact factor: 4.104
  10 in total
  1 in total

1.  Poor survival with wild-type TP53 ovarian cancer?

Authors:  Kwong-Kwok Wong; Daisy I Izaguirre; Suet-Yan Kwan; Erin R King; Michael T Deavers; Anil K Sood; Samuel C Mok; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-06-22       Impact factor: 5.482
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.